高级检索
当前位置: 首页 > 详情页

The effect of Astragaloside IV on immune function of regulatory T cell mediated by high mobility group box 1 protein in vitro

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Capital Med Univ, Beijing Friendship Hosp, Dept Crit Care Med, Beijing 100050, Peoples R China [2]Chinese Peoples Liberat Army Gen Hosp, Hosp 1, Burns Inst, Dept Microbiol & Immunol, Beijing 100048, Peoples R China [3]Capital Med Univ, Beijing Chaoyang Hosp, Dept Surg Intens Care Unit, Beijing 100020, Peoples R China [4]Capital Med Univ, Beijing Chaoyang Hosp, Dept Obstet & Gynecol, Beijing 100020, Peoples R China
出处:
ISSN:

关键词: High mobility group box 1 protein Regulatory T cell Astragaloside IV T lymphocyte Sepsis

摘要:
High mobility group box 1 protein (HMGB1), a potent pro-inflammatory cytokine, contributes to the pathogenesis of diverse inflammatory and infectious disorders. Some studies have illustrated the potential effect of HMGB1 on regulatory T cells (Tregs). Astragaloside IV (AST IV) isolated from a Chinese herb, Astragalus mongholicus, is known to have a variety of immunomodulatory activities. However, it is not yet dear whether AST IV possesses potential regulatory effect on the pro-inflammatory ability of HMGB1 with subsequent activation of Tregs. This study was carried out to investigate the antagonistic effects of different doses of AST IV on the immune function of Tregs mediated by HMGB1 in vitro. Tregs isolated from the spleens of mice were co-cultured with HMGB1 and/or AST IV. Cell phenotypes of Tregs were analyzed, and the contents of various cytokines in the cell supernatants as a result of co-culture and the proliferation of CD4(+)CD25(-) T cells were determined. Results showed that HMGB1 stimulation resulted in significantly down-regulation of expressions of Tregs cell phenotypes. However, AST IV can rival the suppressing effect of HMGB1 on immune function of Tregs with a dose-dependent in vitro. These results indicate that AST IV has the potential therapeutic action on inflammation augmented by HMGB1. (C) 2012 Elsevier B.V. All rights reserved.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2011]版:
大类 | 4 区 医学
小类 | 4 区 药物化学 4 区 药学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 药物化学 3 区 药学
JCR分区:
出版当年[2010]版:
Q2 CHEMISTRY, MEDICINAL Q3 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q3 CHEMISTRY, MEDICINAL Q3 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2010版] 出版当年五年平均[2006-2010] 出版前一年[2009版] 出版后一年[2011版]

第一作者:
第一作者单位: [1]Capital Med Univ, Beijing Friendship Hosp, Dept Crit Care Med, Beijing 100050, Peoples R China [2]Chinese Peoples Liberat Army Gen Hosp, Hosp 1, Burns Inst, Dept Microbiol & Immunol, Beijing 100048, Peoples R China [3]Capital Med Univ, Beijing Chaoyang Hosp, Dept Surg Intens Care Unit, Beijing 100020, Peoples R China
通讯作者:
通讯机构: [2]Chinese Peoples Liberat Army Gen Hosp, Hosp 1, Burns Inst, Dept Microbiol & Immunol, Beijing 100048, Peoples R China [*1]Chinese Peoples Liberat Army Gen Hosp, Hosp 1, Burns Inst, Dept Microbiol & Immunol, 51 Fucheng Rd, Beijing 100048, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:817 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)